JAK2 and acute myeloid leukemia: In cytogenetically normal acute myeloid leukemia, ME1 activates the interleukin (IL)-6/Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway, which correlates with poor prognosis [44].